XENETIC BIOSCIENCES, INC. Gain (Loss) on Extinguishment of Debt
XENETIC BIOSCIENCES, INC. (XBIO) reported Gain (Loss) on Extinguishment of Debt of $0 for the 12-month period ending 2021-12-31, per its 10-K filed 2022-03-22.
Discontinued › Expense Statement › Operating Expenses
us-gaap:GainsLossesOnExtinguishmentOfDebt · last filed 2022-03-22
- XENETIC BIOSCIENCES, INC. gain (loss) on extinguishment of debt for the quarter ending 2020-12-31 was $0.00.
- XENETIC BIOSCIENCES, INC. gain (loss) on extinguishment of debt for the quarter ending 2020-09-30 was $0.00.
- XENETIC BIOSCIENCES, INC. gain (loss) on extinguishment of debt for the quarter ending 2019-12-31 was $0.00.
- XENETIC BIOSCIENCES, INC. gain (loss) on extinguishment of debt for the quarter ending 2019-09-30 was $0.00.
- XENETIC BIOSCIENCES, INC. gain (loss) on extinguishment of debt for fiscal 2021 was $0.00, a 100.00% decline from fiscal 2020.
- XENETIC BIOSCIENCES, INC. gain (loss) on extinguishment of debt for fiscal 2020 was $143.64K.
- XENETIC BIOSCIENCES, INC. gain (loss) on extinguishment of debt for fiscal 2019 was $0.00.
- XENETIC BIOSCIENCES, INC. gain (loss) on extinguishment of debt for fiscal 2017 was $0.00.
| Period end | Gain (Loss) on Extinguishment of Debt 3 month | Gain (Loss) on Extinguishment of Debt 6 month | Gain (Loss) on Extinguishment of Debt 9 month | Gain (Loss) on Extinguishment of Debt 12 month |
|---|---|---|---|---|
| 2021-12-31 | $0.00 10-K · filed 2022-03-22 | |||
| 2020-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2022-03-22 | $0.00 derived: sum of 2 quarters · filed 2022-03-22 | $143.64K 10-K · filed 2022-03-22 | |
| 2020-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2020-11-12 | $143.64K 10-Q · filed 2020-11-12 | ||
| 2020-06-30 | $143.64K 10-Q · filed 2020-08-12 | |||
| 2019-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2021-03-16 | $0.00 derived: sum of 2 quarters · filed 2021-03-16 | $0.00 10-K · filed 2021-03-16 | |
| 2019-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2020-11-12 | $0.00 10-Q · filed 2020-11-12 | ||
| 2019-06-30 | $0.00 10-Q · filed 2020-08-12 | |||
| 2017-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2018-03-30 | $0.00 derived: sum of 2 quarters · filed 2018-03-30 | $0.00 derived: sum of 3 quarters · filed 2018-03-30 | $0.00 10-K · filed 2018-03-30 |
| 2017-09-30 | $0.00 10-Q · filed 2017-11-14 | $0.00 derived: sum of 2 quarters · filed 2017-11-14 | $0.00 10-Q · filed 2017-11-14 | -$207.58K derived: sum of 4 quarters · filed 2018-03-30 |
| 2017-06-30 | $0.00 10-Q · filed 2017-08-14 | $0.00 10-Q · filed 2017-08-14 | -$207.58K derived: sum of 3 quarters · filed 2018-03-30 | -$207.58K derived: sum of 4 quarters · filed 2018-03-30 |
| 2017-03-31 | $0.00 derived: 10-K 12 month − 3 quarters · filed 2018-03-30 | -$207.58K derived: sum of 2 quarters · filed 2018-03-30 | -$207.58K derived: sum of 3 quarters · filed 2018-03-30 | -$6.39M derived: sum of 4 quarters · filed 2018-03-30 |
| 2016-12-31 | -$207.58K derived: 10-K 12 month − 10-Q 9 month · filed 2018-03-30 | -$207.58K derived: sum of 2 quarters · filed 2018-03-30 | -$6.39M derived: sum of 3 quarters · filed 2018-03-30 | -$6.39M 10-K · filed 2018-03-30 |
| 2016-09-30 | $0.00 10-Q · filed 2017-11-14 | -$6.19M derived: sum of 2 quarters · filed 2017-11-14 | -$6.19M 10-Q · filed 2017-11-14 | |
| 2016-06-30 | -$6.19M 10-Q · filed 2017-08-14 | -$6.19M 10-Q · filed 2017-08-14 | ||
| 2015-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2017-03-31 | $0.00 derived: sum of 2 quarters · filed 2017-03-31 | $0.00 derived: sum of 3 quarters · filed 2017-03-31 | $0.00 10-K · filed 2017-03-31 |
| 2015-09-30 | $0.00 10-Q · filed 2016-11-14 | $0.00 derived: sum of 2 quarters · filed 2016-11-14 | $0.00 10-Q · filed 2016-11-14 | |
| 2015-06-30 | $0.00 10-Q · filed 2016-08-15 | $0.00 10-Q · filed 2016-08-15 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| ProPhase Labs, Inc. (PRPH) | United States | $0.006B | -0.06 |
| Processa Pharmaceuticals, Inc. (PCSA) | United States | $0.005B | |
| AMARIN CORP PLC\UK (AMRN) | $0.005B | -247.24 | |
| Pulmatrix, Inc. (PULM) | United States | $0.006B | |
| Ernexa Therapeutics Inc. (ERNA) | United States | $0.006B | |
| Dermata Therapeutics, Inc. (DRMA) | United States | $0.005B | -0.62 |
| REVIVA PHARMACEUTICALS HOLDINGS, INC. (RVPH) | United States | $0.005B | |
| Cadrenal Therapeutics, Inc. (CVKD) | United States | $0.004B | -0.90 |
| Lakewood-Amedex Biotherapeutics Inc. (LABT) | United States | $0.004B | |
| Enveric Biosciences, Inc. (ENVB) | United States | $0.007B | -0.63 |